Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
P53 regulation associated long non-coding RNA (PRAL), also referred to as lncRNA-PRAL, is a long non-coding RNA (lncRNA) molecule involved in post-transcriptional gene silencing and regulation of gene expression related to the p53 pathway[1]. PRAL is upregulated in response to stress signals that activate p53, such as DNA damage. It modulates the expression of a subset of p53 target genes, particularly those involved in cell cycle arrest and survival, rather than directly affecting p53 or p21 levels themselves. This lncRNA acts as a coactivator with specific RNA-binding proteins to facilitate expression of genes related to cell survival after DNA damage, and its dysregulation has been linked to various cancers. PRAL does not represent a traditional therapeutic target such as an enzyme or receptor, but rather functions as a regulatory RNA[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on P53 regulation associated long non-coding RNA (PRAL).